Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Medical Oncology
•
Myeloma
•
Hematology
•
Benign Hematology
•
Liver disease
Is there any diagnostic or therapeutic value in following serum free light chain elevation in patients with cirrhosis?
Related Questions
What are alternative myeloma therapies for patients who are unable to afford lenalidomide or oral cyclophosphamide due to gaps in prescription drug coverage?
Would you complete a bone marrow biopsy for an unexplained macrocytosis without anemia?
What is your approach to MRD testing in the frontline treatment of multiple myeloma?
What is your approach to vaccinations and titers for patients with myeloma, who are immunosuppressed and do not have appropriate antibody responses to vaccines?
How do you discuss harms of MGUS screening with other medical providers?
How do you approach post-transplant maintenance for patients with high-risk myeloma?
Does the presence of osteoporosis change the extent of workup that should be performed for an older patient with otherwise serologically low-risk MGUS?
How would you approach IgM kappa MGUS paraproteinemia with a rising free light chain ratio?
What is the ideal period to wait until curative surgery for patients with acute pulmonary embolism and solid malignancy?
How do you utilize immunoglobulin testing to affect treatment decisions in patients with myeloma?
